Piet van der Graaf on AI and AI-assisted approaches in drug discovery & development
During the American Association of Pharmaceutical Scientists (AAPS) PharmSci 360 2024 conference, Bioanalysis Zone caught up with industry experts across numerous disciplines to discuss their involvement with AAPS and their research. In this interview, we spoke to Piet van der Graaf about his Closing Plenary on AI and AI-assisted approaches in pharmaceutical discovery and development.
Disclaimer: The opinions expressed in this interview are those of the author and do not necessarily reflect the views of Bioanalysis Zone or Taylor & Francis Group.
Piet van der Graaf
Senior Vice President & Head of Quantitative Systems Pharmacology
Certara (PA, USA)
Piet van der Graaf is Senior Vice President and Head of Quantitative Systems Pharmacology at Certara, and Professor of Systems Pharmacology at Leiden University (The Netherlands). From 2013–2016 he was the Director of Research of the Leiden Academic Centre for Drug Research (The Netherlands). From 1999–2013 Piet held various leadership positions at Pfizer (NY, USA) in Discovery Biology, Pharmacokinetics and Drug Metabolism and Clinical Pharmacology. He received his doctorate training in clinical medicine with Nobel laureate Sir James Black at King’s College London and is an elected Fellow of the British Pharmacological Society (both London, UK). He was the recipient of the 2021 Leadership Award from the International Society of Pharmacometrics (NJ, USA) and the 2024 Gary Neil Prize for Innovation in Drug Development from the American Society for Clinical Pharmacology & Therapeutics (VA, USA).
About AAPS
American Association of Pharmaceutical Scientists (AAPS) is a non-profit association of more than 7000 scientists and professionals employed in academia, industry, regulatory and other research related to the pharmaceutical sciences worldwide. Its mission is to advance the capacity of pharmaceutical scientists to develop products and therapies that improve global health, which members pursue through four peer-reviewed journals and a variety of events in person and online.
